Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy
Authors:
Open Access
- 29 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 594110
Abstract
Systemic biomarkers of inflammation, including cytokines and chemokines, are potentially useful in the management of both HIV infection and non-AIDS-defining disorders. However, relatively little is known about the utility of measurement of circulating biomarkers of platelet activation as a strategy to monitor the efficacy of combination antiretroviral therapy (cART), as well as the persistence of systemic inflammation following virally-suppressive therapy in HIV-infected persons. These issues have been addressed in the current study to which a cohort consisting of 199 HIV-infected participants was recruited, 100 of whom were cART-naïve and the remainder cART-treated and virally-suppressed. Fifteen healthy control participants were included for comparison. The study focused on the effects of cART on the responsiveness of three biomarkers of platelet activation, specifically soluble CD40 ligand (sCD40L), sCD62P (P-selectin), and platelet-derived growth factor-BB (PDGF-BB), measured using multiplex suspension bead array technology. Most prominently sCD40L in particular, as well as sCD62P, were significantly elevated in the cART-naïve group relative to both the cART-treated and healthy control groups. However, levels of PDGF-BB were of comparable magnitude in both the cART-naïve and –treated groups, and significantly higher than those of the control group. Although remaining somewhat higher in the virally-suppressed group relative to healthy control participants, these findings identify sCD40L, in particular, as a potential biomarker of successful cART, while PDGF-BB may be indicative of persistent low-level antigenemia.Keywords
This publication has 52 references indexed in Scilit:
- Increased Platelet and Microparticle Activation in HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*HIV Medicine, 2011
- The CD40-CD40L system in cardiovascular diseaseAnnals of Medicine, 2011
- Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot studyHeart and Vessels, 2010
- Antiplatelet therapies for the treatment of cardiovascular diseaseNature Reviews Drug Discovery, 2010
- PDGF‐C and ‐D and their receptors PDGFR‐α and PDGFR‐β in atherosclerotic human arteriesEuropean Journal of Clinical Investigation, 2009
- Nicotine Induces Proinflammatory Responses in Macrophages and the Aorta Leading to Acceleration of Atherosclerosis in Low-Density Lipoprotein Receptor−/−MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery diseaseThe American Journal of Cardiology, 2005
- Soluble CD40LCirculation, 2003
- Effect of Highly Active Antiretroviral Therapy on Thrombocytopenia in Patients with HIV InfectionNew England Journal of Medicine, 1999